Clinical Trial

HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2016 (before its estimated December 2018 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully impact on the development of metastatic disease and the control of preexisting metastasis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2013-07-29; most recent amendment 2016-06-29.
Status change: Active, Not Recruiting → Recruiting 2016-06-29
Status change: Recruiting → Active, Not Recruiting 2016-03-15
Trial Details
NCT Number NCT01913106
Lead Sponsor The Methodist Hospital Research Institute
Conditions Prostatic Neoplasms
Enrollment 25 participants
Start Date 2007-06
Primary Completion 2018-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2016-07-01